Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare and India-based Zydus Cadila have entered into an agreement to form the joint venture company Bayer Zydus Pharma.
Subscribe to our email newsletter
Each party will hold 50% of the shares of the new company, and be equally represented on its management board.
Bayer Zydus Pharma, which will operate in key segments of the Indian pharma market, will focus on women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology.
The new company’s product portfolio will not only include in-licensed and originator brands, but also patented pharmaceuticals from Bayer HealthCare’s pipeline.
The combined portfolio will include popular brands such as Glucobay, Xarelto, Nexavar and Yaz/Yasmin from Bayer HealthCare as well as the products currently marketed by Zydus such as Euglim, Progynova and Ultravist.
Bayer HealthCare AG CEO Jorg Reinhardt said that with this step, the company aims to significantly accelerate their capabilities to better serve the fast growing Indian market.
"We believe that the Joint Venture between Bayer HealthCare and Zydus Cadila will provide a win-win situation for both partners," Reinhardt said.
The new company will be headquartered in Mumbai, India.